PAX5 Antibody
Description
Introduction to PAX5 Antibody
PAX5 antibodies are immunological reagents designed to bind specifically to the PAX5 protein (B-cell lineage-specific activator protein, or BSAP), a transcription factor encoded by the PAX5 gene in humans . These antibodies are used for:
-
Western blotting
-
Immunohistochemistry (IHC)
-
Flow cytometry
-
Immunofluorescence (IF)
PAX5 is expressed throughout B-cell development but is absent in terminally differentiated plasma cells . Its dysregulation is implicated in B-cell malignancies, making PAX5 antibodies vital for diagnostics and research .
Validation and Specificity
PAX5 antibodies are rigorously validated across multiple platforms. Key validation data from R&D Systems' monoclonal antibody (MAB3487) include:
This antibody shows no cross-reactivity in T-cell lines (e.g., Jurkat) , ensuring specificity for B-cell studies.
Role in B-Cell Development
PAX5 antibodies have elucidated the protein’s dual regulatory functions:
-
Gene activation: Promotes B-cell identity by activating lineage-specific genes (e.g., CD19, BLNK) .
-
Gene repression: Suppresses non-B-cell genes (e.g., NOTCH1) .
Studies using PAX5 antibodies revealed its interaction with chromatin-remodeling complexes to establish B-cell-specific gene expression .
Plasma Cell Differentiation
PAX5 downregulation is essential for plasma cell formation. Antibody-based ELISPOT assays demonstrated that sustained PAX5 expression:
Clinical Significance
PAX5 antibodies are indispensable in diagnosing hematopoietic malignancies:
Technical Considerations
Product Specs
Target Background
PAX5 is a transcription factor crucial for B-lymphocyte lineage commitment in lymphoid progenitors. It exhibits a dual function: repressing genes inappropriate for B-lineage development while simultaneously activating B-lineage-specific genes. This multifaceted role encompasses regulation of cell adhesion and migration, induction of V(H)-to-D(H)J(H) recombination, facilitation of pre-B-cell receptor signaling, and promotion of maturation to the mature B-cell stage. Furthermore, PAX5's repression of the cohesin-release factor WAPL induces global changes in pro-B cell chromosomal architecture, contributing to the generation of a diverse antibody repertoire. In the context of microbial infection, PAX5 plays a vital role in maintaining Epstein-Barr virus (EBV) genome copy number by promoting EBNA1/oriP-dependent binding and transcription. It also participates in inhibiting lytic EBV reactivation through modulation of viral BZLF1 activity.
The following studies highlight the diverse functional roles of PAX5:
- PAX5-ELN's oncogenic role in B-cell acute lymphoblastic leukemia (PMID: 30257940).
- PAX5 gene methylation as a prognostic and predictive biomarker in esophageal squamous cell carcinoma (PMID: 29099287).
- Pax-5's regulation of miRNAs, including miR-215, and its impact on breast cancer cell aggressiveness (PMID: 30194145).
- The association between Pax5 deletion and survival in pediatric precursor B-cell acute lymphocytic leukemia (PMID: 28886309).
- The AHR's role in regulating human B cell development through transcriptional alterations of PAX5 (PMID: 28978690).
- The critical role of Pax5 in pre-B cell proliferation and survival (PMID: 27016671).
- A mechanism of transcriptional regulation involving p27, Pax5, and PCAF (PMID: 28158851).
- Pax-5's induction of E-cadherin expression in breast cancer cells (PMID: 28076843).
- The association of PAX5-KIDINS220 fusion with Philadelphia-like acute lymphoblastic leukemia (PMID: 27870151).
- Lower Pax5 expression in antibody-secreting cells compared to naive B cells or plasmablasts (PMID: 27525369).
- The relevance of PAX5, CD19, and ZAP70 status in non-Hodgkin lymphoma diagnosis and treatment (PMID: 27748274).
- B cell receptor signaling component SYK's role in PAX5 tyrosine phosphorylation and its effect on BLIMP1 promoter repression (PMID: 27181361).
- PAX5 haploinsufficiency and its association with tumorigenesis, genomic instability, and immune tolerance (PMID: 28316978).
- The diagnostic utility of PAX5 and IKZF1 abnormalities in B-ALL (PMID: 28214896).
- The potential of GATA5, WT1, and PAX5 methylation markers in hepatocellular carcinoma (PMID: 27171388).
- Gene promoter methylation signatures (WT1, MSH6, GATA5, and PAX5) as predictive biomarkers in oral squamous cell carcinoma (PMID: 27491556).
- The association of PAX5 expression with aggressive clinical course in olfactory neuroblastoma (PMID: 27543867).
- PAX5 expression in combined Merkel cell carcinoma (PMID: 27322785).
- PAX5 as an epigenetically inactivated tumor suppressor in non-small-cell lung cancer (PMID: 26843424).
- The insufficient contribution of single-allele PAX5 mutations to B-ALL development (PMID: 26782422).
- PAX5 methylated imprint margins and their potential association with recurrence in head and neck squamous cell carcinoma (PMID: 26304463).
- The leukemogenicity of PAX5-PML and the role of Blnk in leukemia cell survival (PMID: 26703467).
- PAX5 deletion as an independent risk factor for disease-free survival in pediatric B-ALL (PMID: 27097569).
- The role of differential PAX5 levels in mantle cell lymphoma progression, drug resistance, and prognosis (PMID: 26073757).
- A novel complex variant translocation involving PAX5 in plasma cell myeloma (PMID: 25633778).
- LCK up-regulation, over-activation, and STAT5 hyper-phosphorylation in PAX5 translocated patients (PMID: 25595912).
- Increased PAX5 hypermethylation in triple-negative breast cancer (PMID: 25684485).
- The association of PAX5 gene translocation with B-cell precursor acute lymphoblastic leukemia (PMID: 25304615).
- The potential of PAX5 promoter methylation in gastric cancer prognosis (PMID: 25277182).
- The immunoreactivity expression patterns of PAX2, PAX5, and PAX8 in pediatric small round cell tumors (PMID: 24897005).
- PAX5-JAK2's impact on PAX5 downstream transcriptional program and Janus kinase-STAT signaling in leukemogenesis (PMID: 25515960).
- Placenta growth factor-mediated downregulation of paired box protein 5 and its role in pulmonary hypertension in sickle cell anemia (PMID: 25403488).
- PAX5 as a novel EBER2-interacting protein (PMID: 25662012).
- Distinctive features of leukemia-associated PAX5 fusion proteins (PMID: 24435167).
- MCOLN2's transcriptional activation by PAX5 and its roles in B cell development and function (PMID: 25445271).
- The association between PAX6 downregulation and ocular surface damage in Sjögren's syndrome (PMID: 25228544).
- The infrequent occurrence of somatic PAX5 mutation in multiple myelomas and DLBCL (PMID: 23737402).
- Low PAX5 expression in atypical non-Langerhans cell histiocytic tumor post acute lymphoblastic leukemia (PMID: 24569775).
- The insufficiency of PAX5 expression with DNA demethylation/histone acetylation in inducing B-cell phenotype in Hodgkin Reed-Sternberg cells (PMID: 23842424).
- The frequency of PAX5 gene alterations in B cell acute lymphoblastic leukemia with 9p abnormalities (PMID: 24078568).
- The role of PAX5 alterations in the pathogenesis of pre-B cell ALL (PMID: 24013638).
- Deregulated MAP kinase signaling in t(8;21) AML and its impact on PAX5 association with polycomb complexes (PMID: 23616623).
- PAX5's role in promoting Epstein-Barr virus latency through regulation of BZLF1 (PMID: 23678172).
- Expression patterns of PAX5 and PAX8 in B-cell and T-cell neoplasms (PMID: 23163626).
- PAX5 and TdT expression in Merkel cell carcinomas (PMID: 23329999).
- The dual role of PAX5/ETV6 in PAX5 haploinsufficiency and B-cell development block (PMID: 23090680).
- PAX5 as a direct target of SOX11 (PMID: 23321250).
- The role of reduced huPax5 expression in fixing lymphoid progenitor development (PMID: 22927250).
- Pax-5's key role in phenotypic transitioning during metastasis through FAK1 regulation (Review, PMID: 21707507).
- PAX5 as a functional tumor suppressor in gastric carcinogenesis (PMID: 22105368).
